Endotis Pharma Obtains R&D of €4.5M from Public Sources
By James Etheridge
Wednesday, October 15, 2008
BioWorld International Correspondent
PARIS - Endotis Pharma, which is developing small-glyco drugs for applications in thrombosis and oncology, has obtained public funding of €4.5 million (US6.1 million) from three sources to finance ongoing research programs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.